Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$378,084 | -$481,447 | -$583,194 | -$383,577 |
| Dep. & Amort. | $17,714 | $18,911 | $17,958 | $15,391 |
| Deferred Tax | $4,843 | $0 | $5,377 | -$367 |
| Stock-Based Comp. | $95,512 | $66,660 | $64,180 | $66,830 |
| Change in WC | -$107,157 | -$96,257 | -$12,472 | -$47,721 |
| Other Non-Cash | $60,975 | $24,772 | $12,452 | -$68,205 |
| Operating Cash Flow | -$306,197 | -$467,361 | -$495,699 | -$417,649 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,427 | -$2,442 | -$14,489 | -$23,704 |
| Net Acquisitions | $0 | $0 | $0 | -$10,187 |
| Inv. Purchases | $0 | $0 | -$213,842 | -$226,038 |
| Inv. Sales/Matur. | $7,353 | $0 | $280,528 | $149,880 |
| Other Inv. Act. | $950 | $288,916 | $9,535 | -$530 |
| Investing Cash Flow | $6,876 | $286,474 | $61,732 | -$110,579 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $122,793 | $125,818 | $496,925 | -$6,429 |
| Stock Issued | $309,913 | $0 | $0 | $367,884 |
| Stock Repurch. | $0 | -$1,812 | -$105,305 | -$21,605 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $11,223 | $10,286 | $5,153 | $11,537 |
| Financing Cash Flow | $443,929 | $134,292 | $396,773 | $351,387 |
| Forex Effect | $22,771 | -$6,008 | $35,694 | $38,591 |
| Net Chg. in Cash | $167,379 | -$52,603 | -$1,500 | -$138,250 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $392,164 | $444,767 | $446,267 | $584,517 |
| End Cash | $559,543 | $392,164 | $444,767 | $446,267 |
| Free Cash Flow | -$307,624 | -$469,803 | -$510,188 | -$441,883 |